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Autophagy, a vesicular pathway involving the lysosomal degradation of cytosolic contents, is frequently
hijacked by intracellular pathogens to optimize their infectivity. In this issue of Cell Host & Microbe,
Ding et al. (2014) show that human parainfluenza virus exploits autophagy by targeting SNAREs and prevent-
ing the SNAP29-Stx17 interaction, an otherwise crucial event in autophagosome-lysosome fusion.In mammalian cells, vesicular trafficking
is a highly selective process that delivers
specific substrates and functional com-
ponents to the appropriate cellular com-
partments. Among the various proteins
that ensure this selectivity, SNAREs drive
specific tethering and vesicle fusion.
Typically, a single SNARE (R-SNARE)
resides on a donor membrane and forms
a complex with two or three SNAREs
(Qabc-SNAREs) on the targeted vesicular
membrane (Hong and Lev, 2014), result-
ing in membrane fusion. Recently, spe-
cific SNAREs were identified to directly
regulate the macroautophagy vesicular
pathway (Moreau et al., 2011; Itakura
et al., 2012).
Macroautophagy, usually referred to
as autophagy, is a major cell intrinsic
mechanism of digestion, dedicated to
the recycling of obsolete cytosolic mate-
rial such as damaged organelles or
protein aggregates (Boya et al., 2013).
Autophagy is also a catabolic process
used by cells to fight intracellular patho-
genic intruders (Deretic et al., 2013). The
autophagy vesicular pathway is initiated
by the formation of a curved isolation
membrane, the phagophore. Elongation
of the phagophore membrane results in
the encapsulation and ultimate seques-
tration of cytosolic components within a
newly formed double-membrane vesicle
termed the autophagosome. These steps
are controlled by numerous proteins,
including ATG (AuToPhagy-related) pro-
teins (Boya et al., 2013). Soon after auto-
phagosome completion, SYNTAXIN17
(Stx17, Qa-SNARE) associates selectively
with the outer autophagosomal mem-
brane and subsequently binds to endo-somal/lysosomal VAMP8 (R-SNARE) via
an intermediate SNARE, SNAP29 (Qbc-
SNARE) (Itakura et al., 2012). These
interactions catalyze autophagosome-
endosome/lysosome fusion, leading to
the degradation of the entrapped cyto-
solic content within autolysosomes (Fig-
ure 1). As obligatory intracellular patho-
gens, viruses are continually confronted
by autophagy, and most have evolved
strategies to counteract or even hijack
this process to facilitate their replication
(Deretic et al., 2013).
Human parainfluenza viruses (HPIVs)
belong to the Paramyxoviridae family
and are responsible for acute respiratory
infections in young children (<5 years
old) and immunocompromised individ-
uals (Schomacker et al., 2012). Among
the four known serotypes, HPIV3 is the
most frequent cause of hospitalization
and the second most severe pediatric
respiratory disease worldwide due to
optimized viral replication within epithelial
cells of the respiratory tract. Despite this
high burden of disease, to date neither a
vaccine nor antiviral drugs are available
to prevent or treat HPIV3 infection.
HPIV3 is an enveloped virus with a
negative single-strand nonsegmented
RNA genome which contains six indepen-
dent genes encoding structural proteins
that mediate the following: host cell infec-
tion (the Hemagglutinin-Neuraminidase
HN, and fusion F proteins), intracellular
viral replication (the nucleoprotein N, the
large polymerase L, and the phospho-
protein P), and shaping and budding
newly formed infectious viral particles
(the matrix M protein). P is central in the
viral replication, as it ensures its tran-Cell Host & Microbescription by acting as a cofactor for L,
allowing its anchorage to N-RNA tem-
plates. The P gene of paramyxoviruses
also encodes two accessory proteins
devoted to the modulation of anti-/pro-
viral cellular functions: C, which is en-
coded by an internal open reading frame,
making C totally distinct from P; and
V, whose translation is initiated by the
same initial codon as P, before an
editing process shifts the frame of the
messenger; as a consequence, three
quarters of the N-terminal region of V
are identical to P. Strikingly, with HPIV1,
HPIV3 is the only paramyxovirus that
synthesizes little to no V (Schomacker
et al., 2012).
In this issue, Ding et al. (2014) examine
the role of autophagy in the course of
HPIV3 infection and show that HPIV3
inhibits autophagy. HPIV3 infection of
several epithelial/fibroblast cell lines, as
well as of primary human pulmonary
fibroblasts, leads to the accumulation
of autophagosomes due to HPIV3-medi-
ated inhibition of the autophagosome
maturation step. In subsequent studies
examining how HPIV3 blocks autophagy
maturation, Ding et al. determine that
the viral P protein binds to the Qbc-
SNARE SNAP29. Among the viral struc-
tural proteins, only the single expres-
sion of P phenocopied the prevention
of autolysosome formation mediated
by HPIV3. This was elegantly confirmed
by the observation that downregulation
of P expression in the course of HPIV3
infection reduced the ability of HPIV3
to alter autophagy maturation. Looking
for the molecular mechanism underly-
ing this process, Ding and colleagues15, May 14, 2014 ª2014 Elsevier Inc. 519
Figure 1. HPIV3-P Blocks Autophagosome-Lysosome Fusion
Complete autophagy flux starts with a phagophore, which elongates to form
an autophagosome and becomes an autolysosome upon lysosome fusion
(1). SNAP29 bridges the autophagosomal Stx17 and the lysosomal VAMP8
to mediate autophagosome-lysosome fusion (2). This process is prevented
by the phosphoprotein P of HPIV3, which competes with Stx17 for SNAP29
binding (3). As a result, HPIV3 release is increased via a mechanism involving
the matrix M protein of HPIV3, which is enriched onmembranes potentially via
an autophagosomal rerouting process (4).
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cific target of P, and further
mapped the two SNARE
domains of SNAP29 and the
first N-terminal 100 amino
acids of P as essential for
this interaction. Strikingly,
HPIV3 infection or expres-
sion of P alone disrupts
the cellular SNAP29-Stx17
interaction without affecting
the SNAP29-VAMP8 interac-
tion. Thus, the P-SNAP29
interaction is distinct from
SNAP29-Stx17 binding and
prevents autophagosome-
lysosome fusion (Figure 1). By
contrast, the P-SNAP29 and
the P-N interaction sites are
independent, suggesting that
P-mediated replication does
not compete with its function
in inhibiting autophagy.
HPIV3-mediated inhibition
of autophagy maturation was
determined to improve viral
release. Complete inhibition
of autophagy decreases therelease of infectious particles, without
impacting viral protein synthesis or intra-
cellular viral assembly, whereas drug-
mediated inhibition of autolysosome acid-
ification increases viral release. Similarly,
when using nonsaturating conditions of
HPIV3 infection, reduced SNAP29 ex-
pression increased extracellular viral
particle formation. Importantly, whereas
SNAP29 was previously appreciated to
regulate different various vesicular path-
ways (endocytosis, exocytosis, phagocy-
tosis, and recycling), its function in
extracellular HPIV3 viral particle produc-
tion is predominantly (if not exclusively)
dependent on the autophagy pathway,
since a double deficiency in ATG5 (abro-
gating the complete autophagic process)
and SNAP29 abrogated the effects of
the SNAP29 deficiency on viral release.
Thus, autophagy is not essential for viral
replication, but inhibition of the matura-
tion step is crucial for optimal budding of
HPIV3 from infected cells.
How is autophagy inhibition beneficial
for virus release? The authors determine
that the observed increase in virion pro-
duction is possibly the result of increased
M-mediated virus release. The authors
took advantage of the function of M in
the release of paramyxovirus particles520 Cell Host & Microbe 15, May 14, 2014 ª2and even virus-like particles (VLPs) from
the plasma membrane. In cells express-
ing M only, the inhibition of autophagy
maturation leads to increased VLP
release, M accumulation in membrane
fractions, and some colocalization of M
with vesicles positive for the autophagy
marker, LC3. These observations suggest
that autophagosomes could be rerouted
to the plasma membrane upon HPIV3
infection to favor viral budding (Figure 1).
This work identifies a distinct mecha-
nism by which a virus can alter auto-
phagy, and adds to a growing list of
unique mechanisms that viruses use to
alter this cellular process, an important
point to consider if and when developing
antiviral therapies involving this pathway.
Indeed, contrary to measles virus (MeV),
which requires complete autophagy
flux to optimize its replication (Joubert
et al., 2009; Richetta et al., 2013),
HPIV3, another paramyxovirus, requires
an incomplete autophagy pathway (Ding
et al., 2014). Thus, the ability of P to
alter autophagosome-lysosome fusion is
unexpected and not a general character-
istic of the Paramyxoviridae family (as
not found for MeV and since the N-termi-
nal moiety of P is poorly conserved
among paramyxoviruses), but might be014 Elsevier Inc.shared by some HPIV sero-
types. Strikingly, the absence
of V expression, which other-
wise would share complete
identity with the SNAP29-
binding region of P, could limit
the impact of HPIV3 (and
HPIV1?) on autophagy. It re-
mains to be determined pre-
cisely how P regulates both
viral replication and auto-
phagy. One possibility is that
newly synthesized P first con-
tributes to viral replication
and that later during infection,
excess P regulates virus
release by preventing auto-
phagosome-lysosome fusion.
Although HPIV3 blocks
autophagosome maturation,
it remains unclear whether
infection could also induce
de novo autophagosome for-
mation. As for MeV, HPIV3
could increase autophagy
flux through the expression
of C and/or the formation
of syncytia (Gre´goire et al.,2011; Schomacker et al., 2012; Richetta
et al., 2013), which would further enhance
the release of new viral particles. How
exactly autophagosomes contribute to
viron release is another incompletely
resolved question (Figure 1). Is M inte-
grated within the autophagosomal mem-
brane, and does it drive autophagy-medi-
ated virion budding? Is such a retrograde
trafficking facilitated by virus-targeted
SNAREs?
The more we will learn about direct
molecular orchestration of autophagy,
the more we will learn about the virulence
potential of viruses. The recent identifica-
tion of SNAREs directly involved in the
autophagy process has expanded our
understanding of how viruses can manip-
ulate autophagy, as evidenced by the
findings of Ding and colleagues.
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Children with sickle cell disease (SCD) have significantly increased risk of invasive pneumococcal disease. In
this issue ofCell Host &Microbe, Carter et al. (2014) report that pneumococcal strains fromSCD children have
genetic mutations associated with the unique SCD environment, which need to be considered in developing
new vaccines.Streptococcus pneumoniae (the pneu-
mococcus) colonizes the nasopharynx of
humans and in some circumstances can
cause invasive diseases such as pneu-
monia, meningitis, and bacteraemia. This
organism is genetically variable and can
exchange DNA by the process of genetic
recombination with the occurrence of
more than 90 different serotypes, reflect-
ing the ability of the organism to exchange
capsular gene loci. Selective pressures
on the pneumococcal population, such
as use of antibiotics and vaccines, drive
the emergence of genetic variants with
altered capsule type or antibiotic targets.
The pneumococcus is therefore highly
adaptable to its environment and can
change rapidly in response to interven-
tions. The use of clinical interventions is
known to have a marked effect on pneu-
mococcal population structure (Croucher
et al., 2011). It is also recognized that
even single-nucleotide polymorphisms
may have an effect on the ability of the
pneumococcus to cause disease. A single
nucleotide difference in the genomes of
pneumococci taken from the blood and
cerebrospinal fluid (CSF) of a patient
with meningitis altered the expression
of an ABC transporter. This mutation
changed the virulence of the organism inmouse models of disease and also its
ability to grow in different environments
in vivo (Croucher et al., 2013). Genetic
variation of bacterial pathogens is there-
fore an important facet of the dynamic
host pathogen interaction and of great
consequence for the rationale of design
of new vaccines and treatments for infec-
tious diseases. The host environment,
and the interventions used to prevent
or treat disease, drives genetic variation
of the pneumococcus. The host envi-
ronment can be very different in some
populations, and susceptibility to pneu-
mococcal infection is known to vary in
these populations.
Children with sickle cell disease (SCD)
are at extremely high risk of fatal pneu-
mococcal infection, having a 600-fold
increased risk of fatal invasive pneu-
mococcal disease (IPD) (Overturf, 1999).
The increased infection risk has been
related to functional asplenia and comple-
ment deficiency, but SCD patients also
have altered plasma levels of zinc, iron,
purines, amino acids, and carbohydrates
(Darghouth et al., 2011; Prasad et al.,
1976). Given the high susceptibility to
pneumococcal infection, children with
SCD are routinely immunized with pneu-
mococcal vaccines and administeredprophylactic antibiotics alongside. The
pneumococcus therefore encounters a
very different environment in the sickle
cell patient to that found in the general
population (GP) in terms of host meta-
bolism and exposure to interventions.
In this issue of Cell Host & Microbe,
Carter et al. (2014) analyze and compare
the genomic sequences of more than
320 pneumococcal strains isolated from
carriage and disease in the GP and in chil-
dren with SCD. This analysis reveals that
the different host environments encoun-
tered in SCD lead to specific pneu-
mococcal adaptations associated with
colonization or disease in the SCD host,
as depicted in Figure 1. The vaccines
used to prevent pneumococcal disease
protect against a limited number of sero-
types chosen based on their likelihood to
cause disease in humans. It is well known
that use of these vaccines drives a shift
away from these types and an increase
in prevalence of capsule types not
included in the vaccine (so-called non-
vaccine types, or NVTs). NVTs are
considered to be less able to cause dis-
ease in the GP. A shift toward NVTs was
observed when vaccines were used in
both SCD and GP. The invasive potential
of NVT isolates was examined in a mouse15, May 14, 2014 ª2014 Elsevier Inc. 521
